Glenmark Pharmaceuticals growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+27.5%+12.8%−9.1%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+94.5%+96.7%−47.5%
+114.4%+204.1%−63.2%
+30.1%+173.0%−479.8%
+30.0%+169.7%−605.4%
+24.0%+11.8%−25.9%
+18.8%+12.8%−20.2%
+516.3%−211.8%−142.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

GLENMARK₹2,339.00

Glenmark Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersDRREDDYLUPINALKEMBIOCONMANKINDLAURUSLABSFORTISAUROPHARMAMcap ₹66,007 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—-9.1+12.8+27.5—
EBITDA Growth—-47.5+96.7+94.5—
EBIT Growth—-63.2+204.1+114.4—
Net Income Growth—-479.8+173.0+30.1—
EPS Growth—-605.4+169.7+30.0—
Total Assets Growth—-25.9+11.8+24.0—
Total Equity Growth—-20.2+12.8+18.8—
Cash from Operations Growth—-142.4-211.8+516.3—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.